CompletedNCT01686815
Glucose and Metabolic Measures in People Taking Iloperidone
About this title
Read the official source — NCT01686815Observational studyAges 18–65United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- BostonSee all locations and recruitment
Study information
Study start dateOctober 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 37
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01686815
- Official title
Show the full official title
Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Who was this study for?
Listed age limits: 18 years to 65 years.
